ArticleJournal of neural transmission (Vienna, Austria : 1996)2020
Prevalence and sort of pharmacokinetic drug-drug interactions in hospitalized psychiatric patients.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Prevalence and solving strategies of drug-related problems in adult psychiatric inpatients - a systematic review.Frontiers in psychiatry · 2024Pooled it
- Article
- Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study.The pharmacogenomics journal · 2026Article
- Exploratory prescribing risk profiles and drug drug interaction burden in older adults with depressive episodes.Frontiers in psychiatry · 2026Article
- PsychoPharm aggregated risk score (PARS): a multidimensional tool to flag high-risk pharmacotherapy in psychiatric patients.Frontiers in pharmacology · 2026Article
- Discordance in Drug-Drug Interaction Alerts for Antidotes: Comparative Analysis of Electronic Databases and Interpretive Insights from AI Tools.Drug design, development and therapy · 2025Article
- Evaluation of potentially significant drug-drug interactions among patients receiving psychotropic medications: A real-world retrospective study.Qatar medical journal · 2025Article
- Bupropion Increased More than Five Times the Systemic Exposure to Aripiprazole: An In Vivo Study inMetabolites · 2024Article
- Factors associated with potential drug-drug interactions in psychiatric inpatients.European journal of hospital pharmacy : science and practice · 2024Article
- Deep learning-enabled natural language processing to identify directional pharmacokinetic drug-drug interactions.BMC bioinformatics · 2023Article
- Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients.Frontiers in genetics · 2023Article
- Impact of Cytochrome Induction or Inhibition on the Plasma and Brain Kinetics of [Pharmaceutics · 2022Article
- Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.European journal of clinical pharmacology · 2022Article
- Clinically Significant Cytochrome P450-Mediated Drug-Drug Interactions in Children Admitted to Intensive Care Units.International journal of clinical practice · 2022Article
- The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug-Drug Interactions: Drug-Gene, Drug-Gene-Gene and Drug-Drug-Gene Interactions.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.PloS one · 2021Article
- Prevalence of Polypharmacy and Inappropriate Medication in Adults With Intellectual Disabilities in a Hospital Setting in Switzerland.Frontiers in psychiatry · 2021Article
- Assessment of potential drug interactions among psychiatric inpatients receiving antipsychotic therapy of a secondary care hospital, United Arab Emirates.Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychiatric patients are high-risk patients for the development of pharmacokinetic drug-drug interactions (DDIs), leading to highly variable (victim) drug serum concentrations. Avoiding and targeting high-risk drug combinations could reduce preventable adverse drug reactions (ADRs). Pharmacokinetic cytochrome P450 (CYP)-mediated DDIs are often predictable and, therefore, preventable. The retrospective, longitudinal analysis used informations from a large pharmacovigilance study (Optimization of pharmacological treatment in hospitalized psychiatric patients study, study number 01VSF16009, 01/2017), conducted in 10 psychiatric hospitals in Germany. Medication data were examined for the co-prescription of clinically relevant CYP inhibitors or inducers and substrates of these enzymes (victim drugs). In total, data from 27,396 patient cases (45.6% female) with a mean (mean ± standard deviation (SD)) age of 47.3 ± 18.3 years were available for analysis. CYP inhibitors or inducers were at least once prescribed in 14.4% (n = 3946) of the cases. The most frequently prescribed CYP inhibitors were melperone (n = 2504, 28.1%) and duloxetine (n = 1324, 14.9%). Overall, 51.0% of the cases taking melperone were combined with a victim drug (n = 1288). Carbamazepine was the most frequently prescribed CYP inducer (n = 733, 88.8%). Combinations with victim drugs were detected for 58% (n = 427) of cases on medication with carbamazepine. Finally, a DDI was detected in 43.6% of the cases in which a CYP inhibitor or inducer was prescribed. The frequency of CYP-mediated DDI is considerably high in the psychiatric setting. Physicians should be aware of the CYP inhibitory and inducing potential of psychotropic and internistic drugs (especially, melperone).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.